Citations

Mayo Clinic

Showing 10 of 108602 citations.

A Novel ypTLM Staging System Based on LODDS for Gastric Cancer After Neoadjuvant Therapy: Multicenter and Large‐Sample Retrospective Study
Que, Si‐Jin, Zhong, Qing , Truty, Mark J. , Yan, Su , Ma, Yu‐Bin , Ding, Fanghui , Zheng, Chao‐Hui , Li, Ping , Wang, Jia‐Bin , Lü, Jun, Cao, Long‐Long, Lin, Ju‐Li , Zheng, Hua‐Long , Huang, Chang‐Ming , Chen, Qi‐Yue , Lin, Jian‐Xian , Lin, Mi , Tu, Ru‐Hong

World Journal of Surgery | April 17, 2023 | Volume: 47 | Issue: 7 | Pages: 1762-1771

10.1007/s00268-023-06994-7 | PMID 37069317 Get It

AbstractBackgroundThe accuracy of the eighth AJCC ypTNM staging system on the prognosis of gastric cancer (GC) patients after neoadjuvant therapy (NAT) is controversial. This study aimed to develop and validate a novel staging system using the log odds of positive lymph nodes scheme (LODDS).MethodsA retrospective analysis of 606 GC patients who underwent radical gastrectomy after neoadjuvant therapy was conducted as the development cohort. (Fujian Medical University Affiliated Union Hospital (n = 183), Qinghai University Affiliated Hospital (n = 169), Mayo Clinic (n = 236), Lanzhou University First Hospital (n = 18)). The validation cohort came from the SEER database (n = 1701). A novel ypTLoddsS (ypTLM) staging system was established using the 3‐year overall survival. The predictive performance of two systems was compared. ResultsTwo‐step multivariate Cox regression analysis in both cohorts showed that ypTLM was an independent predictor of overall survival of GC patients after neoadjuvant therapy (HR: 1.57, 95% CI: 1.30–1.88, p < 0.001). In the development cohort, ypTLM had better discrimination ability than ypTNM (C‐index: 0.663 vs 0.633, p < 0.001), better prediction homogeneity (LR: 97.7 vs. 70.9), and better prediction accuracy (BIC: 3067.01 vs 3093.82; NRI: 0.36). In the validation cohort, ypTLM had a better prognostic predictive ability (C‐index: 0.614 vs 0.588, p < 0.001; LR: 11,909.05 vs. 11,975.75; BIC: 13,263.71 vs 13,328.24; NRI: 0.22). The time‐dependent ROC curve shows that the predictive performance of ypTLM is better than ypTNM, and the analysis of the decision curve shows that ypTLM achieved better net benefits. ConclusionA LODDS‐based ypTLM staging system based on multicenter data was established and validated. The predictive performance was superior to the eighth AJCC ypTNM staging system.
Escaping the Long Shadow Cast by Agranulocytosis
León, José de , Arrojo, Manuel , Verdoux, Hélène , Ruan, Can‐Jun , Schoretsanitis, Georgios , Rohde, Christopher , Cohen, Dan , Schulte, Peter F.J. , Kim, Se Hyun , Cotes, Robert O. , Leung, Jonathan G. , Otsuka, Yuji , Кирилочев, О.О. , Every‐Palmer, Susanna , Clark, Scott R. , Motuca, Mariano , Wilkowska, Alina , Yağcıoğlu, A. Elif Anıl , Lazáry, Judit , Sanz, Emílio J. , Cuevas, Carlos De las , de Leon, Jose , Arrojo-Romero, Manuel , Kirilochev, Oleg O , Baptista, Trino , Grover, Sandeep , Every-Palmer, Susanna , Clark, Scott , McGrane, Ian , Motuca, Mariano , Olmos, Ismael , Wilkowska, Alina , Sagud, Marina , Ignjatovic Ristic, Dragana , Lazary, Judit , Sanz, Emilio J , Leung, Jonathan G , Ruan, Can-Jun , Kim, Se Hyun , Rohde, Christopher , De Las Cuevas, Carlos , Schulte, Peter F J , Anıl Yağcıoğlu, A Elif , Cotes, Robert O , Otsuka, Yuji , Schoretsanitis, Georgios , McGrane, Ian R. , Ristić, Dragana Ignjatović

Journal of Clinical Psychopharmacology | April 17, 2023 | Volume: 43 | Issue: 3 | Pages: 239-245

10.1097/jcp.0000000000001678 | PMID 37068034 Get It

Abstract Purpose/Background A recent article in this journal presented a US perspective regarding the modernization of clozapine prescription and proposed an escape from the long shadow cast by agranulocytosis. Methods Here, an international group of collaborators discusses a point of view complementary to the US view by focusing on worldwide outcomes of clozapine usage that may be uneven in terms of frequency of clozapine adverse drug reactions. Findings/Results Studies from the Scandinavian national registries (Finland and Denmark) did not find increased mortality in clozapine patients or any clear evidence of the alleged toxicity of clozapine. Data on clozapine-associated fatal outcomes were obtained from 2 recently published pharmacovigilance studies and from the UK pharmacovigilance database. A pharmacovigilance study focused on physician reports to assess worldwide lethality of drugs from 2010 to 2019 found 968 clozapine-associated fatal outcomes in the United Kingdom. Moreover, the United Kingdom accounted for 55% (968 of 1761) of worldwide and 90% (968 of 1073) of European fatal clozapine-associated outcomes. In a pharmacovigilance study from the UK database (from 2008 to 2017), clozapine was associated with 383 fatal outcomes/year including all reports from physicians and nonphysicians. From 2018 to 2021, UK clozapine-associated fatal outcomes increased to 440/year. Implications/Conclusions The interpretation of fatal outcomes in each country using pharmacovigilance databases is limited and only allows gross comparisons; even with those limitations, the UK data seem concerning. Pneumonia and myocarditis may be more important than agranulocytosis in explaining the uneven distribution of fatal outcomes in clozapine patients across countries.
Low‐grade adenosquamous carcinoma of the breast: a clinical, morphological and immunohistochemical analysis of 25 patients
Lewis, Gloria J., Fong, Nancy, Gjeorgjievski, Sandra Gjorgova , Li, Xiaoxian , Li, Zaibo , Wei, Shi, Sturgis, Charles D. , Wang, Chunjie , Komforti, Miglena K. , Downs, Erinn, Cui, Xiaoyan , Rowe, J. Jordi, Zhang, Gloria, Komforti, Miglena, Hoda, Raza S , Zhang, Gloria , Lewis, Gloria, Zhang, Huina , McIntire, Patrick J. , Hoda, Raza S. , Sciallis, Andrew P.

Histopathology | April 17, 2023 | Volume: 83 | Issue: 2 | Pages: 252-263

10.1111/his.14917 | PMID 37067767 Get It

AimsDue to its rarity and non‐specific clinical and pathological features, low‐grade adenosquamous carcinoma (LGASC) of the breast continues to pose diagnostic challenges. Unlike other triple‐negative breast carcinomas, LGASC tends to have an indolent clinical behaviour. It is essential to recognise this lesion for accurate diagnosis and appropriate management.Methods and resultsTwenty‐five cases of LGASC were identified in our archives and collaborating institutes. Cases of LGASC with dominant coexisting other type carcinomas were excluded. We studied the clinical presentation, morphological features, patterns of the commonly used immunohistochemical stains and follow‐up. In our cohort, LGASC was commonly located at the outer aspect of the breast and associated with intraductal papilloma. The morphology of LGASC is characterised by infiltrating small glands and nests with variable squamous differentiation. We also found cuffing desmoplastic (fibrolamellar) stromal change in 75% of patients and peripheral lymphocytic aggregates in 87.5% of patients. P63 and smooth muscle myosin (SMM) were the most common myoepithelial markers used to assist in diagnosis. P63 often stained peripheral tumour cells surrounding invasive glands (circumferential staining in 80% of the cases), mimicking myoepithelial cells. It also stained the small nests with squamous differentiation. However, SMM was negative in 63% of the cases. The vast majority of our cases were triple‐negative; only a few had focal and weak expressions of ER and PR. One patient who did not have excision developed lymph node metastasis. Most patients underwent excision or mastectomy with negative margins as surgical treatment; there were no recurrences or metastases in these patients with clinical follow‐ups up to 108 months.ConclusionsLGASC has some unique, although not entirely specific, morphological features and immunohistochemical staining patterns. Fibrolamellar stromal change, peripheral lymphocytic aggregates and variable staining of p63 and SMM are valuable features to facilitate the diagnosis.
RAB27B Drives a Cancer Stem Cell Phenotype in NSCLC Cells Through Enhanced Extracellular Vesicle Secretion
Meneses, Kayleah M. , Pandya, Prita , Lindemann, Jennifer A. , Al-Qasrawi, Dania S. , Argo, Ryan A. , Weems, Celeste M. , Beetler, Danielle J. , Vijay, Geraldine V. , Yan, Irene K. , Wolfram, Joy , Justilien, Verline , Patel, Tushar , Justilien, Verline , Wolfram, Joy , Pandya, Prita , Patel, Tushar

Cancer Research Communications | April 17, 2023 | Volume: 3 | Issue: 4 | Pages: 607-620

10.1158/2767-9764.crc-22-0425 | PMID 37077938 Get It

Cancer stem cells (CSC) within non–small cell lung carcinoma (NSCLC) tumors drive NSCLC progression, metastasis, relapse, and intrinsic chemoresistance. Understanding the mechanisms that support the malignant phenotypes of NSCLC CSCs may provide insights for improved NSCLC therapeutic interventions. Here, we report that expression of RAB27B, a small GTPase, is significantly upregulated in NSCLC CSCs when compared with bulk cancer cells (BCC). Short hairpin RNA–mediated knockdown of RAB27B leads to a loss of stem cell marker gene expression and reduced NSCLC spheroid growth, clonal expansion, transformed growth, invasion, and tumorigenicity. We find that NSCLC CSCs secrete significantly more extracellular vesicles (EV) than BCCs, and that this is RAB27B-dependent. Furthermore, CSC-derived EVs, but not BCC-derived EVs, induce spheroid growth, clonal expansion, and invasion in BCCs. Finally, RAB27B is required for CSC-derived EV-induced stemness in BCCs. Taken together, our results indicate that RAB27B is required for maintenance of a highly tumorigenic, cancer-initiating, invasive stem-like cell population in NSCLC and RAB27B is involved in propagating EV-mediated communication from NSCLC CSCs to BCCs. Our findings further suggest that inhibition of RAB27B-dependent EV secretion may be a potential therapeutic strategy for NSCLC. Significance: Expression of RAB27B in CSCs leads to elevated levels of EVs that mediate communication between CSCs and BCCs that maintains a stem-like phenotype in NSCLC cells.
Symptomatic non-stenotic carotid disease: current challenges and opportunities for diagnosis and treatment
Kappelhof, Manon , Kallmes, David F. , Brinjikji, Waleed , Goyal, Mayank , Kappelhof, Manon , Ganesh, Aravind , Brinjikji, Waleed , Goyal, Mayank , Ospel, Johanna M. , Ganesh, Aravind

Journal of NeuroInterventional Surgery | April 17, 2023 | Volume: 16 | Issue: 4 | Pages: 418-424

10.1136/jnis-2022-020005 | PMID 37068939 Get It

Symptomatic non-stenotic carotid plaques (SyNC) are an under-researched and under-recognized source of stroke. Various imaging markers of non-stenotic carotid plaques that are associated with stroke risk have been identified, but these causal relationships need to be confirmed in additional prospective studies. Currently, there exists neither a standardized SyNC definition nor a dedicated set of imaging protocols, although researchers have started to address these shortcomings. Moreover, many neuroradiologists are still unaware of the condition, and hence do not comment on high-risk plaque features other than stenosis in their reports. Regarding SyNC treatment, scant data exist as to whether and to what extent medical, interventional and surgical treatments could influence the course of the disease; the relative lack of data on the ‘natural’ history of untreated SyNC makes treatment comparisons difficult. In our opinion, endovascular SyNC treatment represents the most promising treatment option for SyNC, since it allows for targeted elimination of the embolic source, with few systemic side effects and without the need for general anesthesia. However, currently available carotid devices are designed to treat stenotic lesions, and thus are not optimally designed for SyNC. Developing a device specifically tailored to SyNC could be an important step towards establishing endovascular SyNC treatment in clinical practice. In this review, we provide an overview of the current state of evidence with regard to epidemiological, clinical and imaging features of SyNC, propose a SyNC definition based on imaging and clinical features, and outline a possible pathway towards evidence-based SyNC therapies, with a special focus on endovascular SyNC treatment.
National Institutes of Health grant funding for cerebrovascular diseases
Kobeissi, Hassan , Jabal, Mohamed Sobhi , Ghozy, Sherief , Naylor, Ryan M. , Kadirvel, Ramanathan , Brinjikji, Waleed , Kallmes, David F. , Arul, Santhosh , Kadirvel, Ram , Brinjikji, Waleed , Ghozy, Sherief , Kobeissi, Hassan

Journal of NeuroInterventional Surgery | April 17, 2023 | Volume: 16 | Issue: 2 | Pages: 209-212

10.1136/jnis-2023-020374 | PMID 37068940 Get It

Background Federal research funding is highly sought after but may be challenging to attain. A clear understanding of funding for specific diseases, such as cerebrovascular disorders, might help researchers regarding which National Institutes of Health (NIH) institutes fund research into specific disorders and grant types. Objective To examine the current scope of NIH grant funding for cerebrovascular conditions. Methods The NIH-developed RePORTER was used to extract active NIH-funded studies related to cerebrovascular diseases through January 2023. Duplicate studies were removed, and projects were manually screened and labeled in subcategories as clinical and basic science and as research subcategories. Extracted data included total funding, grant types, institutions that received funding, and diseases studied. Python (version 3.9) and SciPy library were used for statistical analyses. Results We identified 1232 cerebrovascular projects across seven diseases with US$699 952 926 in total funding. The cerebrovascular diseases with the greatest number of grants were ischemic stroke (705, or 57.2% of all funded projects), carotid disease (193, or 15.7%), and hemorrhagic stroke (163, or 13.2%). R01 grants were the most common mechanism of funding (632 grants, or 51.3%). The National Institute of Neurological Disorders and Stroke (NINDS) funded the most projects (504 projects; US$325 536 405), followed by the National Heart, Lung, and Blood Institute (NHLBI) (376 projects; US$216 784 546). Conclusion Cerebrovascular disease receives roughly US$700 million in NIH funding. Ischemic stroke accounts for the majority of NIH-funded cerebrovascular projects, and R01 grants are the most common funding mechanism. Notably, NHLBI provides a large proportion of funding, in addition to NINDS.
Daratumumab-lenalidomide and daratumumab-pomalidomide in relapsed lenalidomide-exposed or refractory multiple myeloma
Abdulazeez, Mays F , Sher, Taimur , Alegria, Victoria R., Warsame, Rahma , Rasheed, Ahsan , Kourelis, Taxiarchis , Kapoor, Prashant , Dingli, David , Hayman, Suzanne R. , Reeder, Craig B. , Chanan‐Khan, Asher , Alhaj Moustafa, Muhamad, Warsame, Rahma M, Chanan-Khan, Asher A., Dingli, David , Moustafa, Muhamad Alhaj , Parrondo, Ricardo D , Roy, Vivek , Fonseca, Rafaël , Gonsalves, Wilson I. , Buadi, Francis K. , Ailawadhi, Sikander

Anti-Cancer Drugs | April 17, 2023 | Volume: 35 | Issue: 1 | Pages: 63-69

10.1097/cad.0000000000001520 | PMID 37067996 Get It

Daratumumab is an anti-CD38 mAb, used frequently in combination with lenalidomide and pomalidomide. No studies compared daratumumab plus lenalidomide and dexamethasone (DRd) to daratumumab plus pomalidomide and dexamethasone (DPd) in lenalidomide-exposed multiple myeloma. We identified 504 consecutive multiple myeloma patients who received daratumumab at Mayo Clinic between January 2015 and April 2019. We excluded patients who received daratumumab in the first line, received more than four lines of therapy prior to daratumumab use, did not receive lenalidomide prior to daratumumab, or had an unknown status of lenalidomide exposure, and patients who received daratumumab combinations other than DRd or DPd. We examined the impact of using DRd compared to DPd on progression-free survival (PFS) and overall survival (OS) in patients with relapsed/refractory multiple myeloma. Out of 504 patients, 162 received DRd or DPd and were included; 67 were lenalidomide-exposed and 95 were lenalidomide-refractory. DRd was used in 76 (47%) and DPd in 86 (53%) patients. In lenalidomide-exposed multiple myeloma, there was no difference in median PFS; 34.2 months [95% confidence interval (CI), 22.8–44.6] for DRd compared to 25.2 months (95% CI, 4.9–35.3) for DPd, P = 0.2. In lenalidomide-refractory multiple myeloma, there was no difference in median PFS; 18.6 months (95% CI, 13–32) for DRd compared to 9 months (95% CI, 5.2–14.6) for DPd, P = 0.09. No difference in median OS was observed in DRd compared to DPd. Our study shows combining daratumumab with lenalidomide in patients with prior lenalidomide use is a viable and effective treatment option.
Are 4D Motion Sensors Valid and Reliable for Studying Baseball Pitching?
Loushin, Stacy R. , Verhoeven, Martijn, Christoffer, Daniel J., Camp, Christopher L. , Kaufman, Kenton R.

The American Journal of Sports Medicine | April 17, 2023 | Volume: 51 | Issue: 6 | Pages: 1608-1614

10.1177/03635465231166423 | PMID 37067847 Get It

Background: Baseball pitching injuries are on the rise. Inertial measurement units (IMUs) provide immediate feedback to players and coaches, allowing for collection outside of the traditional laboratory setting with real-world application. The 4D Motion system provides kinematics throughout the pitching motion and may be beneficial for individualized programs in the throwing athlete. A systematic analysis of these sensors has not been completed. Purpose: To evaluate the validity of the 4D Motion IMU system for analyzing the baseball pitching motion compared with marker-based motion capture, and evaluate the internal reliability and consistency of the device. Study Design: Controlled laboratory study. Methods: Ten high school pitchers participated in this study (10 male; 9 right-hand dominant; mean age, 16.6 ± 1.3 years; mean body mass index, 24.1 ± 3.9). Participants were simultaneously outfitted with six 4D Motion IMU sensors and retroreflective markers. The pitchers threw fastballs at maximum effort off a mound at the standard height and distance. A comparison was made between the IMUs and corresponding motion capture values for shoulder external rotation, elbow flexion, chest extension, pelvis and chest rotation velocity, and rotation acceleration. Results: Significant differences were found for 5 of 7 metrics analyzed. The IMU overreported most metrics, except for elbow flexion and pelvis rotation angular acceleration, where both positive and negative errors were observed. The root mean square error and percentage errors indicated smaller discrepancies for chest extension (4°± 5°) and pelvis (38 ± 19 deg/s) and chest (96 ± 42 deg/s) rotation velocity, with elbow flexion having the largest variance (21°± 9°). Conclusion: The values of the 4D Motion IMU system should not be considered equivalent when compared with marker-based motion capture studies. The system lacked internal consistency and reliability, with angular velocities being the most consistent. Caution should be used when using the metrics provided by an IMU-based system for individualized monitoring. Clinical Relevance: If found valid and reliable, IMUs could be used for longitudinal workload monitoring, individualized throwing and rehabilitation programs, and ultimately injury prevention. This study demonstrates that the data obtained from a 4D Motion system using Gen 3 sensors are not equivalent to the data obtained from a marker-based motion capture system.
Epicardial Fat in Heart Failure with Preserved Ejection Fraction: Bad Actor or Just Lying Around?
Oduah, Mary-Tiffany , Sundaram, Varun , Reddy, Yogesh N.V. , Reddy, Yogesh Nv, Nishimura, Rick

Cardiac Failure Review | April 17, 2023 | Volume: 9 | Issue: No issue available | Pages: No page available

10.15420/cfr.2022.25 | PMID 37397241 Get It

Heart failure with preserved ejection fraction (HFpEF) is increasingly recognised to be strongly associated with obesity and abnormalities in fat distribution. Epicardial fat has been associated with abnormal haemodynamics in HFpEF, with potential for direct mechanical effects on the heart causing constriction-like physiology and local myocardial remodelling effects from secretion of inflammatory and profibrotic mediators. However, patients with epicardial fat generally have more systemic and visceral adipose tissue making determination of causality between epicardial fat and HFpEF complex. In this review, we will summarise the evidence for epicardial fat being either directly causal in HFpEF pathogenesis or merely being a correlate of worse systemic inflammatory and generalised adiposity. We will also discuss therapies that directly target epicardial fat and may have potential for treating HFpEF and elucidating the independent role of epicardial fat in its pathogenesis.
It is time to expand the fatty liver disease community of practice
Lazarus, Jeffrey V. , Kopka, Christopher J. , Younossi, Zobair M. , Allen, Alina M. , Lazarus, Jeffrey V , Allen, Alina M , Kopka, Christopher J

Hepatology | April 17, 2023 | Volume: 78 | Issue: 5 | Pages: 1325-1328

10.1097/hep.0000000000000411 | PMID 37067242 Get It